LACTOLOGY FOUNDATION

A08AA01 — Phentermine

ATC class and general pharmacology

ATC code A08AA01 corresponds to phentermine, a centrally acting anti-obesity medicine classified within A08AA: centrally acting anti-obesity products. The WHO ATC/DDD Index lists an oral defined daily dose of 15 mg.atcddd.fhi

Phentermine is a sympathomimetic amine with pharmacological properties related to amphetamine-type stimulants. It is prescribed as a short-term adjunct to calorie restriction, behavioural modification, and physical activity for management of exogenous obesity in appropriately selected adults. Approved use is generally limited to a few weeks, rather than prolonged maintenance pharmacotherapy.accessdata.fda+1

Its anorectic action is primarily attributed to central nervous system stimulation and increased catecholaminergic signalling, particularly noradrenergic activity, which reduces appetite and food intake. The precise contribution of appetite suppression versus broader central and metabolic effects has not been fully established. Sympathomimetic activity may also increase heart rate and blood pressure.accessdata.fda+1

After oral administration, peak plasma concentrations are reported approximately 3–4.4 hours after dosing. Renal elimination is important; reported cumulative urinary excretion ranges from 62% to 85%, with urinary pH influencing excretion. This pharmacokinetic profile, along with its relatively prolonged stimulant activity, is relevant when considering possible persistence in maternal plasma and potential exposure of a breastfed infant.dailymed.nlm.nih

Toxicological profile

The principal toxicological concerns of phentermine arise from its central stimulant and peripheral sympathomimetic effects. Common adverse effects may include insomnia, restlessness, nervousness, irritability, tremor, dry mouth, constipation, headache, tachycardia, palpitations, and blood-pressure elevation. Central nervous system stimulation and increased blood pressure are characteristic effects of amphetamine-like anorectic agents.dailymed.nlm.nih

Clinically significant cardiovascular toxicity can include hypertension, tachyarrhythmia, chest discomfort, and exacerbation of pre-existing cardiovascular disease. Caution is required even in mild hypertension. Phentermine is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, agitated states, a history of drug abuse, and during or shortly after monoamine oxidase inhibitor therapy; concurrent or recent MAOI exposure carries a risk of hypertensive crisis.fda+1

As a Schedule IV controlled substance in the United States, phentermine also has clinically relevant misuse, abuse, dependence, and withdrawal potential. High-dose or prolonged use may increase the risk of psychological dependence, stimulant-related behavioural toxicity, and adverse cardiovascular effects. Because its pharmacological activity resembles that of amphetamines, accidental exposure in an infant would raise concern for agitation, disturbed sleep, tremor, poor feeding, tachycardia, hypertension, and impaired weight gain.

Lactation pharmacology and infant exposure

Direct human lactation pharmacokinetic data for phentermine are inadequate. There are no well-established published measurements of phentermine concentrations in human milk, infant serum concentrations, relative infant dose, or systematically documented outcomes in exposed breastfed infants. MotherToBaby likewise notes that studies on phentermine use during breastfeeding have not been conducted.mothertobaby

Nevertheless, transfer into milk cannot be excluded. Phentermine is a low-molecular-weight, orally bioavailable sympathomimetic stimulant with sustained maternal systemic exposure. These characteristics create a biologically plausible potential for milk transfer and clinically meaningful infant absorption, although the magnitude of exposure remains unknown.

The absence of measured milk concentrations should not be interpreted as evidence of safety. In this setting, the primary concern is not a quantified relative infant dose but the combination of uncertainty and an adverse-effect profile that could be consequential in young infants. Theoretical infant effects include irritability, excessive wakefulness or insomnia, tremor, altered feeding behaviour, reduced appetite, tachycardia, hypertension, and suboptimal weight gain. A maternal stimulant-related reduction in milk production is also a plausible clinical concern, particularly when lactation is not yet well established, although this has not been adequately quantified for phentermine specifically.

LactMed concludes that phentermine, including phentermine-containing combinations, is not recommended during breastfeeding and that alternatives are preferred. Product information and clinical reference sources similarly advise avoiding breastfeeding during treatment or discontinuing the medicine if nursing is to continue.ncbi.nlm.nih+2

Lactological safety assessment and clinical recommendations

Phentermine should be considered not compatible with routine breastfeeding. This assessment is driven by the lack of direct lactation safety data, potential infant exposure to a potent sympathomimetic stimulant, the possibility of clinically relevant cardiovascular and neurobehavioural effects in the infant, and the availability of non-drug approaches to postpartum weight management. LactMed specifically recommends alternative treatments rather than phentermine during breastfeeding.ncbi.nlm.nih

For a lactating individual seeking weight management, first-line care should focus on individualized nutritional support, gradual energy adjustment, physical activity appropriate to postpartum recovery, sleep and mental-health assessment, and evaluation of medical contributors to weight retention. Rapid calorie restriction should be avoided when it threatens maternal nutritional status, milk production, or breastfeeding continuation.

If phentermine is judged clinically necessary, shared decision-making should explicitly address the option of deferring treatment until breastfeeding has ceased. If treatment cannot be postponed, interruption of breastfeeding and use of an appropriate alternative infant-feeding plan should be considered rather than attempting to minimize exposure only by timing feeds around a dose. Because phentermine has sustained systemic activity, dose-timing strategies cannot reliably eliminate infant exposure.infantrisk

Where inadvertent exposure has occurred, clinical evaluation should consider the infant’s age, degree and duration of exposure, prematurity, medical vulnerability, feeding pattern, and symptoms. Monitoring should focus on:

• Poor feeding or reduced appetite
• Excessive wakefulness, irritability, tremor, or unusual crying
• Sleep disruption
• Tachycardia or signs of cardiovascular stimulation
• Inadequate weight gain or reduced milk intake

Urgent paediatric assessment is appropriate if an infant develops marked agitation, persistent feeding refusal, tremor, rapid heartbeat, breathing difficulty, lethargy, or poor weight gain. Decisions about restarting breastfeeding after discontinuation should be individualized with a clinician or a specialist in lactation pharmacology, since the evidence base does not provide a validated milk-clearance interval.